112950 ⎘
Oligonucleotides characterized by their use Toxicological screening, e.g. expression profiles which identify toxicity
COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR
#2NOVEL MICROBIAL GENOTOXINS
#3METHODS FOR SEQUENCING SAMPLES
#4MULTILINEAGE CARDIOVASCULAR ORGANOIDS AND METHODS OF GENERATING THE SAME
#5COMPOSITIONS AND METHODS FOR TREATING VASCULAR MALFORMATION AND RELATED CONDITIONS
#6DETECTING ANTIBIOTIC AND/OR CHEMICAL USE IN ANIMALS USING EPIGENETIC MEANS
#7DETECTING ANTIBIOTIC AND/OR CHEMICAL USE IN AQUATIC ANIMALS USING EPIGENETIC MEANS
#8ALGORITHM AND AN IN VITRO METHOD BASED ON RNA EDITING TO SELECT PARTICULAR EFFECT INDUCED BY ACTIVE COMPOUNDS
#9METHODS FOR SEQUENCING SAMPLES
#10GENOME-WIDE CLASSIFIERS FOR DETECTION OF SUBACUTE TRANSPLANT REJECTION AND OTHER TRANSPLANT CONDITIONS
#11MICROBIOME MARKERS AND THERAPIES FOR AUTISM SPECTRUM DISORDERS
#12BIOMARKER FOR TRICHOTHECENE TOXICITY
#13METHOD FOR DETERMINING THE LIKELIHOOD THAT A SUBJECT HAS OR WILL DEVELOP CANCER
#14EARLY WARNING GENETIC TESTING OF TOXIC CYANOBACTERIA IN WATER SUPPLY
#15INTERROGATORY CELL-BASED ASSAYS FOR IDENTIFYING DRUG-INDUCED TOXICITY MARKERS
#16Methods for sequencing samples
#17Methods for sequencing samples
#18EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS
#19Methods for sequencing samples
#20Methods for sequencing samples
#21BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASES CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME
#22Methods for sequencing samples
#23CRISPR-CAS14A RESPONSE PHOTOELECTROCHEMICAL SENSING DETECTION METHOD AND KIT FOR DETECTING T2 TOXIN
#24Methods and Compositions for Detecting Virulent and Avirulent Escherichia coli Strains
#25Microbiome markers and therapies for autism spectrum disorders
#26MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS
#27METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS
#28ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLS
#29METHOD FOR DETERMINING THE LIKELIHOOD THAT A SUBJECT HAS OR WILL DEVELOP CANCER
#30METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING ENDOMETRIOSIS
#31ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS
#32Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
#33Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
#34INFLAMMATORY BIOMARKER SPECIFIC TO EXPOSURE TO 2-BUTANONE AND IDENTIFICATION METHOD USING SAME
#35METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT
#36IN VITRO NEPHROTOXICITY SCREENING ASSAY
#37DETECTION AND PREDICTION OF INFECTIOUS DISEASE
#38METHODS AND REAGENTS FOR DETECTING AND ASSESSING GENOTOXICITY
#39METHOD FOR THE QUALITY CONTROL OF SEED LOTS
#40GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER
#41GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER
#42Genome-wide classifiers for detection of subacute transplant rejection and other transplant conditions
#43METHOD FOR DETERMINING THE LIKELIHOOD THAT A SUBJECT HAS OR WILL DEVELOP CANCER
#44BIODEGRADATION OF TOXIC ORGANIC COMPOUNDS IN CONTAMINATED ENVIRONMENTS
#45METHODS AND COMPOSITIONS FOR IDENTIFYING AND QUANTIFYING MICROBIAL DNA
#46ANALYTICAL PROCESS FOR GENOTOXICITY ASSESSMENT
#47Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes
#48Method for assisting prediction of risk of occurrence of side effect of irinotecan
#49COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR
#50Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
#51Virus concentration method
#52Cytotoxic Chemotherapy-Based Predictive Assays for Acute Myeloid Leukemia
#53Epigenetic analysis of cell therapy and related methods
#54Micro-fluidic chip and its modification method and application in detection of the quantity of food bacteria
#55Interrogatory cell-based assays for identifying drug-induced toxicity markers
#56METHOD FOR EVALUATING THE EYE IRRITATION POTENTIAL OF CHEMICALS
#57METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS
#58Methods for sequencing samples
#59In vitro nephrotoxicity screening assay
#60Methods and compositions for diagnosing, prognosing, and treating endometriosis
#61ALGORITHM AND AN IN VITRO METHOD BASED ON RNA EDITING TO SELECT PARTICULAR EFFECT INDUCED BY ACTIVE COMPOUNDS
#62Apoptosis regulatory gene detected in irradiated-thymic lymphoma cell and method for detecting same
#63Screening for chemotherapy resistance in human haploid cells
#64Automated priming and library loading device
#65Nano-neurotoxicity bio-marker composition based on intracellular aggregates which are biomarkers of degenerative brain diseases
#66SYSTEMS AND METHODS FOR MODELING DISEASE AND ASSESSING ADVERSE SIDE EFFECTS OF THERAPEUTICS THEREFOR
#67Microbiome markers and therapies for autism spectrum disorders
#68Detection method for DNA repair-related genes which respond to low-level radiation
#69METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS
#70METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS
#71Method of determining cellular protein homeostasis
#72Methods and systems for high-throughput toxicity screening of a compound using mahalanobis values
#73VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS
#74AfArsR gene and prokaryotic host cell
#75METHODS FOR DETERMINING THE CAUSE OF SOMATIC MUTAGENESIS
#76MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
#77IN VITRO GENOTOXICITY ASSAY USING A TRANSCRIPTOMIC BIOMARKER WITH DIRECT DIGITAL COUNTING
#78MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
#79METHOD FOR ASSISTING PREDICTION OF RISK OF OCCURRENCE OF SIDE EFFECT OF IRINOTECAN
#80Compositions and methods for treating vascular malformation and related conditions
#81GDF-15 as a haematological toxicity biomarker
#82Methods for predicting drug responsiveness in cancer patients
#83METHODS AND COMPOSITIONS FOR IDENTIFYING AND QUANTIFYING MICROBIAL DNA
#84Articles for diagnosis of liver fibrosis
#85Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment
#86Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
#87METHODS AND COMPOSITIONS FOR IDENTIFYING AND QUANTIFYING MICROBIAL DNA
#88MICROBIOME MARKERS AND THERAPIES FOR AUTISM SPECTRUM DISORDERS
#89Methods and compositions for detecting fungi and mycotoxins
#90Methods of predicting toxicity
#91In vitro toxicogenomics for toxicity prediction using probabilistic component modeling and a compound-induced transcriptional response pattern
#92EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM
#93METHOD FOR SCREENING RISK OF DRUG-INDUCED TOXICITY
#94Methods Employing Non-Coding RNA Expression Assays
#95Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
#96Anuran cross-species molecular sensors
#97Methods and compositions for detecting fungi and mycotoxins
#98Assay for safety assessment of therapeutic genetic manipulations, gene therapy vectors and compounds
#99Assay for drug discovery based on in vitro differentiated cells
#100ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLS
#101Human pluripotent stem cell-based models for predictive developmental neural toxicity
#102METHODS OF PREDICTING TOXICITY
#103Methods for monitoring methotrexate therapy
#104Microvesicle histone H2AX as a biomarker for genotoxic stress
#105MicroRNAs and uses thereof
#106Methods to protect against and treat multiple sclerosis
#107Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting MUC4 gene polymorphism
#108ASSESSING RISK FOR ENCEPHALOPATHY INDUCED BY 5-FLUOROURACIL OR CAPECITABINE
#109Methods for determining the cause of somatic mutagenesis
#110Novel Gene Targets Associated with Amyotrophic Lateral Sclerosis and Methods of Use Thereof
#111PROMOTER OF DIFFERENTIATION FROM HEPATIC PROGENITOR CELL INTO HEPATIC CELL, AND USE THEREOF
#112IN VITRO ASSAY FOR PREDICTING RENAL PROXIMAL TUBULAR CELL TOXICITY
#113Biosensors for organic and inorganic arsenic
#114Method for determining efficacy of chemotherapy treatment for a subject
#115Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
#116Microbiome markers and therapies for autism spectrum disorders
#117Method for analyzing water toxicity
#118BIOMARKERS FOR INCREASED RISK OF DRUG-INDUCED LIVER INJURY FROM EXOME SEQUENCING STUDIES
#119Anuran cross-species molecular sensors
#120Methods for genome-wide screening and construction of genetic interaction maps
#121DETECTION AND TYPING OF BACTERIAL STRAINS
#122NUCLEIC ACID AMPLIFICATION KITS FOR SPECIFIC DETECTION OF E. COLI O157:H7 WITHOUT CO-DETECTION OF E. COLI O55:H7
#123EDITING PROFILING OF PDE8A PRE -MRNA: USE AS SPECIFIC BIOMARKER OF ADARS ACTIVITIES IN HUMAN TISSUES TO DIAGNOSE AND TO PREDICT AND ASSESS THERAPEUTIC EFFICACY AND/OR EFFICIENCY OR POTENTIAL DRUG SIDE EFFECTS
#124Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
#125Systemic genotoxicity as blood marker for allergic inflammation
#126Detection and Monitoring of Macrocyclic Lactone Resistance in Nematodes
#127Use of microrna molecules to influence skin pigmentation
#128Therapeutic approach for polyglutamine degeneration
#129EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM
#130Mercury methylation genes in bacteria and archaea
#131Antimicrobial agents from microbial genomes
#1321, 2-Dichloropropane-to-Propene Reductive Dehalogenase Genes
#133Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
#134Biomarker for diagnosing toxicity of nanoparticles and method for evaluating toxicity of nanoparticles using the same
#135Method for determining the neurodevelopmental toxicity of a compound in vitro
#136Polynucleotides comprising a reporter sequence operatively linked to a regulatory element
#137Methods for monitoring methotrexate therapy
#138Methods for characterizing kidney function
#139Gene targets associated with amyotrophic lateral sclerosis and methods of use thereof
#140Methods and compositions for detecting fungi and mycotoxins
#141MARKERS AND ASSAYS FOR DETECTION OF NEUROTOXICITY
#142Detecting PAX2 for the diagnosis of breast cancer
#143Detecting PAX2 for the diagnosis of breast cancer
#144Kits And Methods For Assessing Oxidative Stress
#145TOXICITY-ASSOCIATED GENES, GENETIC VARIANTS, AND USE THEREOF
#146METHOD FOR DETERMINING SUBSTANCE NON-TOXICITY
#147USE OF TIGECYCLINE FOR TREATMENT OF CANCER
#148Toxicology and cellular effect of manufactured nanomaterials
#149Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
#150COMPOSITIONS AND METHODS FOR TRICHOMONAS VAGINALIS DIAGNOSTIC TESTING
#151Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platform
#152IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO
#153Methods for Screening for Antibiotic Compounds
#154INTRATUMORAL GENE EXPRESSION LEVELS OF TP AND VEGF ARE ASSOCIATED WITH CLINICAL OUTCOMES IN RECTAL CANCER PATIENTS TREATED WITH 5-FLUOROURACIL AND PELVIC RADIATION
#155ANNEXIN A11 AND ASSOCIATED GENES AS BIOMARKERS FOR CANCER
#156Methods employing non-coding RNA expression assays
#157Detection and typing of bacterial strains
#158Methods for characterizing agonists and partial agonists of target molecules
#159KITS AND METHODS FOR ASSESSING OXIDATIVE STRESS
#160METHOD FOR DETERMINING IMMUNE SYSTEM ACTIVITY AND MEDICAMENT FOR INFLUENCING SAME
#161Methods and kits for ascertaining biosafety of an agent
#162Method for the identification of carcinogenic compounds
#163Methods for stratifying and annotating cancer drug treatment options
#164Compositions and methods relating to monitoring alcohol consumption and alcohol abuse
#165HLA alleles associated with adverse drug reactions and methods for detecting such
#166Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
#167MARKER GENES BASED ON AMIODARONE TREATMENT FOR SCREENING OF DRUG INDUCING PULMONARY TOXICITY AND SCREENING METHODS USING THE SAME
#168PHARMACOLOGICAL APPLICATIONS OF MITOCHONDRIAL DNA ASSAYS
#169VEGF polymorphisms and anti-angiogenesis therapy
#170Method for assessing embryotoxicity
#171Methods for Screening for Antibiotic Compounds
#172USE OF A COX-2 INHIBITOR FOR THE TREATMENT OF A COX-2 DEPENDENT DISORDER IN A PATIENT NOT CARRYING HLA ALLELES ASSOCIATED WITH HEPATOTOXICITY
#173Compositions and Methods for the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis
#174MARKER GENES FOR SCREENING OF DRUG-INDUCED TOXICITY IN HUMAN CELLS AND SCREENING METHOD USING THE SAME
#175POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPOUND-INDUCED OTOTOXICITY
#176METHOD FOR PREDICTION ABOUT CARCINOGENICITY OF SUBSTANCE IN RODENT
#177BRCA1 function-based cellular assays
#178BIOMARKERS FOR THE PREDICTION OF RENAL INJURY
#179Marker Gene For Detection of Tumor Promoter, and Method For Detection of Tumor Promoter
#180ASSAY
#181Nucleic acid compositions and nucleic acid amplification based methods for detecting O157:H7
#182GLOBAL GENE EXPRESSION ANALYSIS OF HUMAN BRONCHIAL EPITHELIAL CELLS EXPOSED TO CIGARETTE SMOKE, SMOKE CONDENSATES, OR COMPONENTS THEREOF
#183Identification and use of genes encoding amatoxin and phallotoxin
#184Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof
#185Method for determining the allergic potential of a compound
#186Genetic Markers for Predicting Disease and Treatment Outcome
#187BIOMARKERS FOR CARDIOVASCULAR SIDE-EFFECTS INDUCED BY COX-2 INHIBITORY COMPOUNDS
#188Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection
#189Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
#190GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF
#191Netrin-1 as a biomarker of injury and disease
#192Novel Methods and Devices for Evaluating Poisons
#193Methods for assessing cancer susceptibility to carcinogens in tobacco products
#194Compositions and methods for the detection of topoisomerase II complexes with DNA
#195Methods For Detection Of Sepsis
#196QUALITATIVE DIFFERENTIAL SCREENING
#197Cisplatin-resistance marker for ovarian tumor
#198DNA CHIP FOR PREDICTION OF OCCURRENCE OF LATE ADVERSE REACTION IN URINARY ORGAN AFTER RADIOTHERAPY, AND METHOD FOR PREDICTION OF OCCURRENCE OF LATE ADVERSE REACTION IN URINARY ORGAN AFTER RADIO THERAPY USING THE SAME
#199Biomarkers For Assessing Altherosclerotic Potential
#200METHODS FOR PREDICTING AND DETECTING INTOLERANCE TO AN HYPOLIPIDEMIC AGENT
#201POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPLEX INDUCED OTOTOXICITY
#202Uses of antimicrobial genes from microbial genome
#203BIOMARKERS FOR ACETAMINOPHEN TOXICITY
#204Biomarkers for Drug-Induced Liver Injury
#205DETECTING PAX2 FOR THE DIAGNOSIS OF BREAST CANCER
#206REAGENT SETS AND GENE SIGNATURES FOR NON-GENOTOXIC HEPATOCARCINOGENICITY
#207Kidney Toxicity Biomarkers
#208Method for confirming the exposure on chrysene
#209Impaired Alleles of Genes Involved in Metabolic Pathways and Methods for Detecting and Using the Same
#210Marker Genes Based on Amiodarone Treatment for Screening of Drug Inducing Toxicity and Screening Method Therefor
#211Toxicology and Cellular Effect of Manufactured Nanomaterials
#212RNA Bioassay
#213In vitro Assay Methods for Classifying Embryotoxicity of Compounds
#214Simultaneous quantification of nucleic acids in diseased cells
#215Biomarkers for toxic algae
#216NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS
#217Genetic polymorphisms for identifying individuals at risk for drug-induced vestibular dysfunction
#218MOLECULAR CARDIOTOXICOLOGY MODELING
#219METHODS OF PREDICTING THE PHARMACEUTICAL TOXICITY OF TAXANES
#220Biomarkers for toxic algae
#221Biomarkers for toxic algae
#222Diagnosis of (a risk of) disease and monitoring of therapy
#223Pharmacological Applications of Mitochondrial DNA Assays
#224METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS OF DIFFERENT GENE VARIANTS
#225Nucleic acid encoding apolipoprotein E-I3
#226Methods for the early diagnosis of ovarian cancer
#227Animal Model for Assessing Copd-Related Diseases
#228METHODS AND KITS BASED ON UGT1A7 PROMOTER POLYMORPHISM
#229Methods For Molecular Toxicology Modeling
#230Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme
#231Methods and Biomarkers for Detecting Nanoparticle Exposure
#232BIOMARKERS FOR TOXIC ALGAE
#233Molecular toxicology modeling
#234Identification and use of biomarkers for non-invasive and early detection of liver injury
#235Compositions and methods for identifying agents that alter expression of survivin
#236Kits and method for determining the risk of adverse effects of irinotecan comprising hybridizing pairs of nucleic acid probes
#237DETECTION AND IDENTIFICATION OF TOXICANTS BY MEASUREMENT OF GENE EXPRESSION PROFILE
#238HLA alleles associated with adverse drug reactions and methods for detecting such
#239KITS AND METHODS FOR ASSESSING OXIDATIVE STRESS
#240Determination of molecular age by detection of expression
#241Evaluation of the Toxicity of Pharmaceutical Agents
#242Global gene expression analysis of human bronchial epithelial cells exposed to cigarette smoke, smoke condensates, or components thereof
#243Neuroactive fragments of APP
#244Pesticidally active proteins and polynucleotides obtainable from species
#245Methods and compositions for detecting fungi and mycotoxins
#246Polymorphisms in the Epidermal Growth Factor Receptor Gene Promoter
#247Use Of Genetic Polymorphisms To Predict Drug-Induced Hepatotoxicity
#248Polymorphisms in voltage-gated sodium channel α 1-subunit as markers for therapy selection
#249GENETIC MARKERS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
#250Genetic Screening for Polymorphisms in Human Genes that Increase or Decrease Sensitivity to Toxic Agents
#251Kit for assessing mitochondrial toxicity
#252Genetic markers of food allergy
#253Methods for increasing cancer cell chemosensitivity
#254Nucleic acid molecules encoding a novel ectoparasite saliva protein
#255Alterations in the copy number of the SULT1A1 gene
#256Molecular nephrotoxicology modeling
#257Biomarkers for toxic algae
#258Molecular nephrotoxicology modeling
#259Molecular cardiotoxicology modeling
#260Diagnosis of (a risk of ) disease and monitoring of therapy
#261Gamma secretase notch biomarkers
#262FABP4 as biomarker for toxic effect
#263Cardiotoxin molecular toxicology modeling
#264Primary rat hepatocyte toxicity modeling
#265Molecular cardiotoxicology modeling
#266Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
#267Simultaneous quantification of nucleic acids in diseased cells
#268Molecular hepatotoxicology modeling
#269Molecular nephrotoxicology modeling
#270Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases
#271Methods for identifying drug pharmacology and toxicology
#272Primers useful in polymerase chain reaction for the identification of subtypes C1, C2 and C3 of staphylococcal enterotoxin type C
#273Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
#274Novel Methods and Devices for Evaluating Poisons
#275Methods for characterizing agonists and partial agonists of target molecules
#276Gene expression profiles and methods of use
#277Canine gene microarrays
#278Methods and compositions for determining non-specific cytotoxicity of a transfection agent
#279Detection and typing of bacterial strains
#280High throughput detection of glutathione s-transferase polymorphic alleles
#281Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof
#282Method for determining susceptibility of an individual to allergen induced hypersensitivity
#283Methods of screening agents for activity using teleosts
#284Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide
#285Drug targets for the treatment of neurodegenerative disorders
#286Methods for determining renal toxins
#287Compositions and methods for the detection of DNA topoisomerase II complexes with DNA
#288Biomarkers and assays for carcinogenesis
#289Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy
#290Biomarkers for toxic algae
#291Canine CYP1A2 genetic polymorphism
#292Methods for obtaining directionally truncated polypeptides
#293Sensitivity test to predict efficacy of anti-cancer therapies
#294RNA bioassay
#295Method of treating lethal shock induced by toxic agents and diagnosing exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
#296Skin substitutes and uses thereof
#297Determining the chemosensitivity of cells to cytotoxic agents
#298Identification of toxic nucleotide sequences
#299Regulated nucleic acids in pathogenesis of Alzheimer's Disease
#300Method for determining cardiotoxicity